December 16, 2019

Joff Masukawa, USA

Joff Masukawa Business Strategies United States Joff Masukawa is president and founder of Diligentia, LLC, a life-sciences consultancy that develops commercial business strategies and tactical commercialization requirements for manufacturers of biopharmaceuticals, cell and gene therapies, diagnostics and health tech, and other novel emerging medical innovations. Diligentia also offers federal and state government and public affairs […]

Joff-Masukawa-2

Joff Masukawa

Business Strategies

United States

Joff Masukawa is president and founder of Diligentia, LLC, a life-sciences consultancy that develops commercial business strategies and tactical commercialization requirements for manufacturers of biopharmaceuticals, cell and gene therapies, diagnostics and health tech, and other novel emerging medical innovations. Diligentia also offers federal and state government and public affairs strategy and tactical lobbying support to facilitate client engagement with policymakers and government agencies in support of business objectives.

Prior to founding Diligentia, Joff was Vice President and Global Head of Government Relations and Public Affairs at Shire, where he designed and led strategies to build the company’s brand, engagement and leadership with government representatives and agencies, patient advocacy groups, payors, industry associations and other key external stakeholders.

Joff has held senior level leadership roles spanning commercial and corporate functions, including market access, government and public affairs, patient and provider services, and sales and marketing at Shire, Genzyme, Visible Genetics, Gentiva and Labcorp. He has developed and executed numerous commercial launch strategies for first-in-class products and is an expert at developing and aligning optimal legislative, regulatory and market access solutions to support business objectives. He began as a clinical sales representative for Merck.

He serves on the board of directors of Caregiver Action Network, The Center for Healthcare Innovation, and ICORD, the International Conference on Rare Diseases and Orphan Drugs. He is a member of the American Society of Cell and Gene Therapy and the Innovation and Value Initiative.